| Name | Title | Contact Details |
|---|---|---|
Chris Hodes |
Regional Sales Director | Profile |
Steve O'Brien |
SVP, Talent Acquisition | Profile |
Hillary Bochniak |
Chief Human Resources Officer | Profile |
Robyn Aycock |
Regional Sales Director-Southeast | Profile |
Stanford Rudnick |
Interim Chief Financial Officer and Chief Strategy Officer | Profile |
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Our products are helping to address some of today`s biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources. We are improving people`s quality of life by preventing, alleviating or curing diseases. We are helping to provide an adequate supply of high-quality food, feed and renewable plant-based raw materials. In line with our mission “Bayer: Science For A Better Life”, we aim to improve people`s quality of life. For this endeavor, we focus on our core competency of developing and successfully commercializing innovative products and solutions based on scientific knowledge.
Trio Health offers a unique collaboration with clinical experts, patients and specialty pharmacies to allow unparalleled insight into patient care. Together with our advisory boards, we created Trio Health MDX, a proprietary system to collect and share information from all three stakeholders. This innovative collaboration provides the patient with unprecedented care thereby improving patient outcomes.
Eastpointe is a Managed Care Organization (MCO) that manages, coordinates, and monitors mental health, intellectual and developmental disabilities, and substance addiction services in the Eastpointe region. We work together with individuals, families, ...
Family Service offers a variety of programs and services focused on increasing opportunities for adults, protecting seniors, reducing substance abuse, improving the lives of those with mental illness, preparing children and adolescents for the future, ...
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.